The purpose of the study is to evaluate the effects of calcium dobesilate (Doxium) on the electroretinographic changes in 60 non-insulin dependent diabetic patients with mild to moderate diabetic retinopathy, randomly assigned to receive either oral calcium dobesilate l000mg twice 8 day for 6 months or without medication. And also the effects of blood HbAlc and retinal photocoaglulation on the electroretinographic changes were evaluated. All patients were tested electroretinography with UTAS-2000 (LKC co., USA) before treatment and six months later respectively. The time interval changes of the electroretinogram were analyzed with student t-test program. As a result, no interval changes of the electroretinographic b-wave amplitudes and b/a ratio were noted in both groups, but the oscillatory potentials were significantly decreased after 6 months in the non-treated group (p:0.002). As compared to calcium dobesilate treated group, the non-treated group with blood HbAlc over 6.5mg% (p:0.008) or treated with retinal photocoagulation (p:0.001) showed a significant decrease of the oscillatory potentials. In conclusion, the administration of calcium dobesilate in the patients with diabetic retinopathy prevents an oscillatory potentials reduction, especially in patients with blood level of HbAlc below 6. 5mg% or treated with retinal photocoagulation.
Calcium Dobesilate ; Calcium* ; Diabetic Retinopathy* ; Electroretinography ; Humans ; Light Coagulation ; Retinaldehyde

The aim of this study is to study the effect of calcium dobesilate on streptozotocin (STZ)-induced early diabetic nephrophathy (DN) in rats. All male Wistar rats were randomly divided into six groups: normal group; DN blank group; calcium dobesilate 75, 150, and 300 mg x kg(-1) groups and perindopril 0.4 mg x kg(-1) group. Blood glucose and the 24 h urinary albumin were measured dynamically during the experiment, after 8 weeks administration, the level of glycosylated hemoglobin (HbA1c) was determined, the expressions of plasminogen activator inhibitor-1 (PAI-1) and matrix metalloprotein-9 (MMP-9) in cortex of kidney were examined with immunohistochemical staining. The endothelin (ET) in plasma and kidney cortex was measured with radioimmunoassay, renal pathomorphism was observed with light and electron microscopes. Calcium dobesilate could decrease the 24 h urinary albumin and ET in plasma and kidney cortex, down-regulate the expression of PAI-1, and up-regulate MMP-9 in kidney. These findings suggested that calcium dobesilate could protect blood vessel endothelium, inhibit kidney fibrous degeneration, ameliorate renal pathological damage, and protect kidney function in many ways.
Albuminuria ; Animals ; Blood Glucose ; metabolism ; Calcium Dobesilate ; pharmacology ; Diabetes Mellitus, Experimental ; blood ; metabolism ; pathology ; Diabetic Nephropathies ; blood ; metabolism ; pathology ; Endothelins ; blood ; metabolism ; Glycated Hemoglobin A ; metabolism ; Hemostatics ; pharmacology ; Kidney Cortex ; metabolism ; ultrastructure ; Male ; Matrix Metalloproteinase 9 ; metabolism ; Plasminogen Activator Inhibitor 1 ; metabolism ; Random Allocation ; Rats ; Rats, Wistar